MPM Medical CoMatryx Surgical Bovine Collagen Study

Overview

The objective of this prospective enrollment study is to collect data confirming safety, performance and clinical benefits of the CoMatryx Surgical Collagen powder at a minimum 1-year follow-up and compare it to a historical control group who did not receive the product at the time of surgery.

The primary objective is to confirm safety and clinical benefits of the product. This will be assessed by recording the rate of wound healing and incidence and frequency of wound care related complications. Relationship of complications to the product should be specified.

Full Title of Study: “The CoMatryx Surgical Collagen Powder is a Soft Tissue Repair Product Made of 100% Type I Bovine Collagen”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 2022

Detailed Description

The CoMatryx Surgical Collagen powder is a soft tissue repair product made of 100% Type I Bovine collagen. It is non-hydrolyzed and not cross-linked chemically. It is biocompatible, biodegradable and free of synthetics. The product does not have any specific storage requirements.

The CoMatryx Surgical Collagen powder provides a physiologically favorable environment to promote healing at the wound site. When administered, the powder conforms to the wound site and forms a gelatinous occlusive barrier. Along with providing 19 amino acids directly to the wound site it also occludes live nerve endings reducing pain. Treating the wound with the CoMatryx Surgical Collagen powder provides the non-hydrolyzed collagen wound surface promoting autolytic debridement. The powder is effective in all phases of wound healing and can be delivered with antibiotics in areas where there may be a cavity. This product has FDA 510(k) clearance for surgical wounds, full thickness wounds, traumatic wounds and skin tears.

Interventions

  • Device: CoMatryx Surgical Bovine Collagen
    • The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen

Arms, Groups and Cohorts

  • Intervention Cohort
    • The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
  • Historical Cohort
    • Primary and Revision total hip arthroplasty patients between 18-85 years of age

Clinical Trial Outcome Measures

Primary Measures

  • CoMatryx Surgical Bovine Collagen
    • Time Frame: This study will require following-up with patients up to 1-year post surgery. The estimated time of completion from enrollment (100 patients) to completing 1 year follow-up is 2 years.
    • The primary objective is to confirm safety and performance of the study product. This will be assessed by recording the rate of healing, incidence and frequency of complications and adverse events relative to the surgical incision at 1-week, 2-week, 6-week, 6-month and 1-year follow-up. Height and Weight will be combined as BMI(kg/m^2)
  • CoMatryx Surgical Bovine Collagen Height and Weight
    • Time Frame: This study will require following-up with patients up to 1-year post surgery. The estimated time of completion from enrollment (100 patients) to completing 1 year follow-up is 2 years.
    • Height and Weight will be combined as BMI(kg/m^2)

Secondary Measures

  • Bovine Collagen
    • Time Frame: This study will require following-up with patients up to 1-year post surgery. The estimated time of completion from enrollment (100 patients) to completing 1 year follow-up is 2 years.
    • The secondary objective is the assessment of clinical benefits by analyzing recorded subject-reported pain scores

Participating in This Clinical Trial

Inclusion Criteria

  • • Subjects must be 18 years of age or older
  • Subject must be willing and able to sign IRB approved informed consent
  • Subject must have a BMI of 35 or higher
  • Surgical approach of only ASI (anterior supine)
  • Primary total hip arthroplasty
  • Revision total hip arthroplasty

Exclusion Criteria

  • • Subjects more than 85 years of age
  • Subjects who will be or have undergone bilateral total hip replacements
  • Subject is known to be pregnant or nursing
  • Subject is an alcohol or drug abuser
  • Subject has a psychiatric illness or cognitive deficit that will not allow for proper informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • MPM Medical
  • Collaborator
    • Texas Health Resources
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kwame Ennin, MD, Principal Investigator, Texas Health Physicians Group
  • Overall Contact(s)
    • Scott Miller, 9728934049, scott.miller@mpmmed.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.